STAT

FEBRUARY 12, 2024

Novo Holdings, the controlling shareholder of Novo Nordisk, plans to invest about $35 billion by 2030 , Reuters writes. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030.

Diabetes 208

Diabetes Vaccines Communication Hospitals 208

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 104

Vaccines 104

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. How could payer views change by 2030? Understanding payer views of preventive care.

Vaccines 130

Vaccines 130

The Guardian - Pharmaceutical Industry

APRIL 7, 2023

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives ‘A silver lining’: how Covid ushered in a vaccines golden era Millions of lives could be saved by a groundbreaking set of new vaccines for a range of conditions including cancer, experts have said.

Vaccines 111

Vaccines 111

STAT

SEPTEMBER 29, 2022

The Covid-19 pandemic set back many of the global health goals for 2030. One of the most feasible to recover is the target of eliminating human deaths from rabies , thanks to an effective, inexpensive vaccine for dogs.

Vaccines 260

Vaccines 260

STAT

JANUARY 12, 2023

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.

Vaccines 241

Vaccines 241

European Pharmaceutical Review

JULY 12, 2023

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunity Immunization Documentation 98

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 98

Vaccines Immunity Immunization 98

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunity Immunization 78

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Vaccines 137

Vaccines Hospitals 137

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

NOVEMBER 13, 2024

Lenacapavir for PrEP could provide an important alternative to existing preventative medications that require more frequent dosing, and could help transform the HIV prevention landscape by addressing a range of unmet needs for individuals who need or want PrEP globally,” Ogbuagu added.

Vaccines 96

Vaccines 96

Express Pharma

SEPTEMBER 20, 2023

The free vaccination camps will be run with support of Brihanmumbai Municipal Corporation (BMC). The ‘Stop Rabies’ initiative aligns with India’s National Action Plan for Dog-Mediated Rabies Elimination by 2030. It adopts a two-pronged approach of vaccination and education.

Vaccines 91

Vaccines 91

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 94

Biosimilars Vaccines 94

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. BioNTech to support trial access for cancer immunotherapies Developing an mRNA cancer vaccine In terms of disease indication, melanoma remains the primary focus of advanced mRNA-based therapies, GlobalData reported.

Immunity 110

Immunity Immunization Vaccines 110

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. If successfully developed, this means cancer vaccines could become part of standard care. Signing of this agreement builds on a memorandum of understanding signed in January.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 110

Vaccines Immunity Immunization Drug Development 110

European Pharmaceutical Review

JANUARY 6, 2023

BioNTech has signed an agreement with the UK Government to help accelerate clinical trials for personalised mRNA immunotherapies, with the aim to provide personalised cancer therapies for up to 10,000 patients by the end of 2030. Infectious disease vaccines. The collaboration will focus on three strategic pillars.

Vaccines 52

Vaccines 52

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 26

Vaccines Immunity Immunization 26

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.

Vaccines 110

Vaccines Communication Documentation Compounding 110

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Immunity 115

Immunity Immunization Vaccines 115

Express Pharma

JANUARY 4, 2024

The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. It meets 50 per cent of the global demand for various vaccines, 40 per cent of the generic demand in the US, and 25 per cent of all medicine in the UK.

Packaging 107

Packaging Labelling Vaccines 107

pharmaphorum

NOVEMBER 6, 2022

The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Vaccines 64

Vaccines Labelling 64

Pharmaceutical Technology

MAY 18, 2023

The World Health Organization (WHO) 2021 roadmap outlines plans to eradicate 20 listed diseases, which include leprosy, scabies and mycetoma, by 2030. Neglected tropical diseases are a major global health concern, affecting over 1.7 billion people, many of whom live in the poorest and most vulnerable communities.

Vaccines 52

Vaccines Compounding 52

Express Pharma

MAY 19, 2024

The COVID-19 pandemic has further elevated the significance of this industry, spotlighting India’s role as a major global player in vaccine production and pharmaceutical R&D. Together, this has led to a surge in real estate demand that is likely to reach approximately 96 million sq ft by 2030 (1).

Vaccines 52

Vaccines Pharmaceutical Manufacturing 52

pharmaphorum

SEPTEMBER 16, 2022

The former blockbuster – first approved back in 1998 – is still making solid sales despite losing patent protection, with AZ booking $410 million from the drug last year, but are expected to drop sharply once Beyfortus and vaccines for RSV prevention reach the market. Both vaccines are also being tested in older adults.

Vaccines 59

Vaccines Immunity Immunization 59

pharmaphorum

MAY 11, 2022

If approved, nirsevimab would provide a new option for managing RSV, ahead of the possible rollout of vaccines that could be used to protect young children. Despite the RSV vaccine threat, analysts at GlobalData have predicted that nirsevimab could reach $3 billion in annual revenue by 2030, assuming a launch next year.

Vaccines 64

Vaccines 64

pharmaphorum

JANUARY 5, 2023

One threat to the new drug is Pfizer’s RSV vaccine, intended for administration to expectant mothers, which is due to generate phase 3 results in this setting in the coming months. Pfizer has already reported late-stage data showing the vaccine is effective in older adults.

Vaccines 52

Vaccines Hospitals 52

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 144

Vaccines Immunity Immunization Hospitals 144

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 101

Vaccines 101

Express Pharma

NOVEMBER 24, 2023

With objectives laid down during the G20 presidency, the industry in India is poised to scale to $65 billion by 2024 and surpass $130 billion by 2030, driven by heightened pharma innovation, technological advancements, and a focus on breakthrough products.

Packaging 96

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 96

Express Pharma

JUNE 14, 2024

It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. India’s pharmaceutical industry is a global powerhouse.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing Packaging 97